Pfizer pulls out of drug trials

Pfizer has halted patient enrolment in a late-stage lung cancer trial of its experimental drug, figitumumab, for safety reasons.<br />The decision was recommended by independent safety monitors overseeing the study. In their review, the monitors found more serious adverse events, including deaths, with patients receiving figitumumab.<br />Pfizer said currently enrolled patients may continue their treatment in consultation with their physicians. As of 30 September, 681 patients were enrolled in the Phase 3 study out of a target of 820.<br />